Assay for human breast cancer
US4803169A · kind A · utility
13Cited by
2References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 5, 1986 |
| Grant date | Feb 7, 1989 |
| Priority date | — |
| Expiry date | Feb 5, 2006 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S436/813
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Methods are disclosed for detecting, staging and monitoring breast cancer. The methods involve determining the amount of certain antigens, designated W1 and W9, in serum via quantitative immunoassays using anti-W1 or anti-W9 monoclonal antibodies. The amount detected is compared with amounts of the antigen found in normal sera, sera from breast cancer patients of predetermined stage, or other samples of the patient's own serum, depending upon the purpose of the assay.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.